JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Replacing 2 Gy Per Fraction Equivalent Dose with Fractionation-Specific Biological Equivalent Dose for Normal Tissues

  • 0Department of Radiation Medicine, University of Kentucky, Lexington, KY 40536, USA.
International Journal of Molecular Sciences +

|

December 17, 2024

|

December 17, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

The fractionation-specific biological equivalent dose (FEQD(n)) offers a realistic approach to normal tissue dose constraints in radiotherapy, unlike the conventional EQD2. FEQD(n) provides accurate dose constraints for various fractionation regimens, improving clinical practice and patient outcomes.

Area Of Science

  • Radiation Oncology
  • Medical Physics
  • Radiobiology

Background

  • The 2 Gy per fraction equivalent dose (EQD2) is widely used for dose prescription and regimen evaluation in radiotherapy.
  • However, EQD2 often misrepresents biological dose for normal tissues, leading to inaccuracies in dose constraints.
  • Existing methods struggle to provide consistent normal tissue dose constraints across different fractionation schedules.

Purpose Of The Study

  • To introduce and validate the fractionation-specific biological equivalent dose (FEQD(n)) as a superior metric for normal tissue dose constraints.
  • To demonstrate the limitations of EQD2 in accurately reflecting normal tissue response to varying fractionation.
  • To provide practical FEQD(n) derived dose constraints for critical normal tissues in clinical use.

Main Methods

  • Defined FEQD(n) based on the linear-quadratic model and biological effective dose (BED), accounting for fractionation number (n).
  • Compared FEQD(n) with EQD2, highlighting differences in representing total dose for target and normal tissues.
  • Derived FEQD(n) dose constraints for brainstem, spinal cord, rectum, and lung based on clinical outcomes and toxicity rates.

Main Results

  • FEQD(n) accurately reflects the total dose for both target and normal tissues across diverse fractionation regimens.
  • EQD2 values derived for targets and normal tissues differ and do not consistently represent the delivered dose.
  • FEQD(n) curves for critical organs (brainstem, spinal cord, rectum, lung) were established for direct clinical application.

Conclusions

  • FEQD(n) is a more realistic and practical tool than EQD2 for establishing normal tissue dose constraints in radiotherapy.
  • The derived FEQD(n) dose constraints can be directly implemented in clinical practice for various fractionation schemes.
  • This approach enhances the accuracy of dose planning and tolerance assessment, improving radiotherapy safety and efficacy.

Keywords: